Comparison of low dose vs standard dose abiraterone in prostate cancer patients

Effect of low dose vs standard dose abiraterone on biochemical failure in metastatic prostate cancers

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120618010057N3

Enrollment

Registered

2022-04-30

Start date

2022-04-30

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer. Malignant neoplasm of prostate

Interventions

Intervention 1: Intervention group: Hormone therapy + docetaxel + low dose abiraterone. Androgen deprivation therapy (ADT)+ docetaxel + abiraterone 250mg daily + prednisolone daily until one year late

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Metastatic prostate cancer patients who are candidates for triplet therapy

Exclusion criteria

Exclusion criteria: Hormone resistant

Design outcomes

Primary

Measure	Time frame
Biochemical free survival. Timepoint: 3 months interval. Method of measurement: Prostate-Specific Antigen (PSA) test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbolfazl Razzaghdoust

Shahid Beheshti University of Medical Sciences

razzaghdoust@sbmu.ac.ir+98 21 2256 7222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026